Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. (NASDAQ: XGN) is a leading provider of advanced diagnostic solutions focused on autoimmune rheumatic diseases. With its headquarters in Carlsbad, California, Exagen operates a CLIA-certified and CAP-accredited laboratory dedicated to improving patient outcomes through innovative testing solutions.
Exagen's core business revolves around its Avise® brand, which encompasses a suite of ten proprietary diagnostic tests designed to provide accurate, timely, and differential diagnoses for autoimmune conditions like systemic lupus erythematosus (SLE) and rheumatoid arthritis. These tests empower physicians and patients with objective data to better manage and treat these complex diseases.
In recent developments, Exagen has entered an exclusive license agreement with Johns Hopkins University to develop novel lupus nephritis biomarkers. This collaboration aims to create non-invasive assays that offer unique clinical insights into lupus nephritis, enhancing diagnostic and treatment options.
Financially, Exagen reported revenue of $13.4 million for Q3 2023. Despite a net loss of $5.4 million for the same period, the company has shown improvements in key performance metrics such as adjusted EBITDA, which stood at $(3.6) million compared to $(6.1) million in Q3 2022. With cash and cash equivalents of $28.4 million as of September 30, 2023, Exagen is well-positioned to continue its growth and innovation.
Committed to personalized medicine, Exagen collaborates closely with community rheumatologists to ensure their diagnostic solutions meet the evolving needs of the medical community. Their focus on patient-centric care and continuous product enhancement underscores their mission to provide clarity in autoimmune disease decision-making.
For more detailed information, please visit the company's websites at exagen.com and avisetest.com.
Exagen Inc. (Nasdaq: XGN), a leader in autoimmune testing, will announce its financial results for Q3 2021 on November 10, 2021, after market close. CEO Ron Rocca, CFO Kamal Adawi, and COO Mark Hazeltine will host a conference call at 4:30 PM ET to discuss the results. The call can be accessed via phone or webcast on the Exagen investor relations website. A replay will be available until November 17, 2021. Exagen focuses on improving patient care through innovative testing solutions for autoimmune diseases like rheumatoid arthritis and lupus.
Exagen Inc. (Nasdaq: XGN) has partnered with Inland Empire Health Plan (IEHP) to provide covered AVISE® CTD and AVISE Lupus services to 1.4 million members. This agreement facilitates in-network access to these diagnostic tests, critical for the timely diagnosis of complex autoimmune diseases, including Systemic Lupus Erythematosus (SLE). The partnership aims to enhance patient outcomes by addressing the challenges in diagnosing and treating SLE, which predominantly affects women of color. Exagen focuses on innovative testing solutions to improve autoimmune disease management.
Exagen Inc. (Nasdaq: XGN) announced a $27.2 million 5-year term loan with Innovatus Capital Partners at an 8.0% interest rate, where 2.0% is paid in-kind. This amendment strengthens their relationship, aiming to enhance patient care for autoimmune diseases through innovative testing solutions. The updated terms were disclosed in a Current Report filed on October 25, 2021. The loan is expected to support Exagen's mission of improving patient outcomes and reducing healthcare costs amidst ongoing challenges within the healthcare landscape.
Exagen Inc. (Nasdaq: XGN) will present new research at the virtual ACR Convergence 2021 from November 6-9, 2021. This research focuses on the role of cell-bound complement activation products (CB-CAPs) in diagnosing and treating systemic lupus erythematosus (SLE). Chief Scientific Officer Anja Kammesheidt expressed pride in collaborating with key researchers. Notable presentations include studies examining the clinical utility of multianalyte assays and CB-CAPs in SLE evaluation. Exagen aims to enhance patient care through advanced diagnostic solutions.
Exagen Inc. (Nasdaq: XGN) will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. Ron Rocca, President and CEO, and Kamal Adawi, CFO, are set to hold a virtual fireside chat on September 27 at 2:40 PM EDT. Interested individuals can access the live webcast through Exagen's website. The company is focused on providing innovative autoimmune testing solutions, particularly for conditions like rheumatoid arthritis and lupus, through its AVISE® brand and proprietary technology.
Exagen Inc. (Nasdaq: XGN) reported record financial results for Q2 2021, achieving total revenue of $12.8 million, a 43% year-over-year increase, and a 21% rise from Q1 2021. Revenue from the AVISE® CTD test reached $10.4 million, marking a 94% increase from the previous year. The company delivered 33,328 tests, reflecting an 80% growth year-over-year. Despite these gains, operating expenses rose to $18.5 million, leading to a net loss of $6.4 million. Exagen maintains its full-year revenue guidance of $47 million to $49 million.
Exagen Inc. (Nasdaq: XGN) has appointed Ms. Ana Hooker as an independent member of its Board of Directors, effective July 29, 2021. Hooker brings extensive experience in clinical laboratories, having held senior roles in organizations like Exact Sciences. The addition is expected to bolster Exagen's growth strategy in autoimmune testing solutions. Exagen aims to enhance patient care through innovative testing products under its AVISE® brand, focusing on complex autoimmune diseases.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Exagen (Nasdaq: XGN) will participate in the Canaccord Genuity 41st Annual Growth Conference from August 10-12, 2021. CEO Ron Rocca and CFO Kamal Adawi will host a virtual fireside chat on August 12 at 12:00 PM EST. The session can be accessed through Exagen’s website.
Exagen aims to advance care for autoimmune disease patients with innovative testing solutions, including products under its AVISE® brand. For more details, visit their website.
Exagen Inc. (Nasdaq: XGN) will announce its financial results for Q2 2021 on August 9, 2021, post-market close. Key executives, including CEO Ron Rocca and CFO Kamal Adawi, will lead a conference call at 4:30 PM Eastern Time to review the results. Interested parties can join the call by phone or through a webcast available on Exagen’s investor relations website. A replay of the call will be accessible until August 16, 2021. Exagen focuses on autoimmune testing solutions, aiming to enhance patient care through its AVISE® brand products.
Exagen Inc. (Nasdaq: XGN) announced the publication of a clinical utility study in Lupus & Science Medicine demonstrating the effectiveness of the AVISE Lupus test. Conducted with 12 rheumatology practices, the study revealed that the AVISE test enhances physician confidence in diagnosing systemic lupus erythematosus (SLE) and informs treatment decisions. The results showed increased certainty in SLE diagnoses with higher AVISE scores. Exagen aims to support rheumatologists in managing autoimmune diseases through innovative testing solutions.
FAQ
What is the current stock price of Exagen (XGN)?
What is the market cap of Exagen (XGN)?
What is Exagen Inc. known for?
Where is Exagen Inc. located?
What recent partnerships has Exagen Inc. entered into?
How did Exagen Inc. perform financially in Q3 2023?
What is the Avise® brand?
How does Exagen Inc. contribute to personalized medicine?
What is Exagen's mission?
What was Exagen's adjusted EBITDA for Q3 2023?
What resources does Exagen offer for lupus awareness?
How can I contact Exagen Inc. for investor relations?
